Niva Bupa Health Insurance Q2 Results Due as EPS Estimate Rises 13%
Key highlights
- Niva Bupa Health Insurance will report Q2 FY27 results on November 4, 2026, with an earnings call scheduled for 5:30 PM IST.
- Consensus FY27 EPS increased 13% to ₹2.04 from ₹1.81, while the ₹9,820 crore revenue forecast was unchanged.
- Q1 FY27 revenue rose 27.9% year on year to ₹2,471 crore and net profit rose 94.4% to ₹138 crore.
- Niva Bupa's retail health market share reached 11.1% in Q1 FY27, compared with 10.1% in FY26.
powered by IRIS

Niva Bupa Health Insurance Company Limited will report its Q2 FY27 results on November 4, 2026, after the consensus FY27 earnings-per-share estimate increased 13% to ₹2.04 from ₹1.81. The revision follows a profitable first quarter in which the insurer reported ₹138 crore of net profit, up 93% year on year.
Know Niva Bupa Health Insurance Company inside out
Results, valuation, peers and who's buying, in one view.
When will Niva Bupa Health Insurance report Q2 FY27 results?
Niva Bupa Health Insurance will announce unaudited financial results for the quarter and half-year ended September 30, 2026 on November 4, 2026. The board meeting to consider and approve the results was scheduled for the same day, according to the company’s October 24 disclosure.
Niva Bupa has also scheduled an earnings conference call at 5:30 PM IST on November 4. Senior executives are expected to discuss the quarterly numbers and provide details available through the company’s investor-call arrangements. The trading window was closed until November 6 in connection with the results process.
The company’s forthcoming release follows its Q1 FY27 results for the quarter ended June 30, 2026. In that period, revenue from operations was ₹2,471 crore, representing year-on-year growth of 27.9%. Net profit was ₹138 crore, up 94.4% year on year, while operating margin improved by 2 percentage points to 7.0%.
Why did the FY27 earnings estimate increase?
Consensus FY27 EPS estimates for Niva Bupa have increased to ₹2.04 from ₹1.81, a rise of 13%. However, the consensus revenue forecast was unchanged at ₹9,820 crore, showing that the revision was based on a higher earnings outlook rather than a change in anticipated revenue.
The updated estimate comes after a June-quarter performance that showed improved profitability. Q1 FY27 EPS was ₹0.75, compared with ₹0.39 in the corresponding quarter a year earlier. It was lower than ₹0.86 reported in the preceding quarter, as quarterly net profit declined 13.6% from ₹159 crore in Q4 FY26 to ₹138 crore in Q1 FY27.
Consensus expects Niva Bupa’s net income to grow 8.3% in the next financial year. This is below the 22% net-income growth forecast for India’s insurance industry cited in the consensus data. The figures provide a benchmark for investors assessing whether the Q2 release supports the company-specific earnings outlook.
What did Niva Bupa report in the previous quarter?
Niva Bupa reported gross written premium of ₹2,150 crore in Q1 FY27, a 32% increase from the year-earlier period. The company said retail health business grew 47%, helping retail health market share increase to 11.1% as of the first quarter from 10.1% in FY26 and 9.4% in FY25.
Under Ind AS, the company’s combined insurance service ratio improved to 100.2% in Q1 FY27, compared with 101.5% in FY26 and 103.0% in FY25. Its claim ratio was 63.0%, versus 64.9% in FY26, while the expense ratio was 37.2%, compared with 36.6% in FY26. The company also reported annualised return on equity of 14.8% for the quarter.
The figures should be viewed alongside the accounting basis used. Under i-GAAP, Niva Bupa reported a net loss of ₹134 crore for Q1 FY27, while its i-GAAP combined ratio was 118.1%. The provided rating information attributes part of the difference to the 1/n accounting method used for long-term policies under i-GAAP. This makes the accounting framework relevant when comparing reported profitability measures.
Niva Bupa’s solvency ratio was 2.25 times in Q1 FY27, compared with 2.49 times in FY26 and 3.03 times in FY25. The rating commentary described capitalisation as comfortable and noted that the ratio remained above the regulatory requirement, although the source does not state the applicable minimum threshold.
Got a follow-up? Ask IRIS
How have Niva Bupa shares and financial trends performed?
Niva Bupa’s share price was ₹87.01 over the week covered by the consensus update, with little change. The consensus price target was ₹94.27 and was broadly unchanged. The difference between these two figures was about ₹7.26, but neither the unchanged target nor the one-week share-price movement establishes a future share-price outcome.
The market reaction to recent quarterly releases has been limited in the supplied data. Following the Q1 FY27 release on July 30, 2026, the share price moved from ₹85.74 before the results to ₹85.92 after them, a gain of 0.2%. After Q4 FY26 results, the share price increased 1.6%, while the Q2 FY26 release was followed by a 1.3% decline.
For FY26, Niva Bupa recorded revenue of ₹6,697 crore, up 21.1%, and net profit of ₹131 crore, down 38.75%. The previous year had revenue of ₹5,530 crore and net profit of ₹214 crore. The financial history illustrates continued revenue growth but also variability in annual profit, making claims trends, underwriting ratios and expenses relevant items for investors to monitor in the September-quarter announcement.
What should investors assess in the November 4 update?
Investors will be able to compare the September-quarter revenue, profit and EPS with the strong Q1 FY27 base and with the FY27 consensus EPS estimate of ₹2.04. The results will also offer updated evidence on whether the company’s retail health growth and market-share gains continued after the June quarter.
Underwriting measures will remain material because the company’s Q1 combined insurance service ratio of 100.2% was close to break-even. Movement in claim and expense ratios can affect profitability even where premium and revenue growth remain strong. The results call may also provide management’s disclosed perspective on operating performance, though no outlook beyond the supplied information is assumed here.
Conclusion
Niva Bupa’s November 4 Q2 FY27 release comes after a 13% increase in the consensus EPS estimate and a Q1 marked by 27.9% revenue growth, ₹138 crore of net profit and higher retail health market share. The available data show improving Ind AS underwriting measures, while also highlighting differences between Ind AS and i-GAAP profitability reporting.
The key scheduled event is the board’s consideration of the September-quarter and half-year results on November 4, followed by the 5:30 PM IST earnings call. Investors can watch for reported revenue, profit, underwriting ratios, solvency disclosures and any management comments that clarify progress against the unchanged ₹9,820 crore FY27 revenue forecast.


